high
casefat
rate
confirm
merscov
infect
underlin
urgent
need
effect
treatment
reduc
diseas
sever
mortal
two
fulli
human
neutral
monoclon
antibodi
mab
merscov
reduc
viru
replic
mice
express
human
upon
prophylact
therapeut
treatment
evalu
prophylact
therapeut
efficaci
common
marmoset
model
merscov
infect
intraven
administr
mab
result
high
level
merscovneutr
activ
circul
blood
anim
treat
mab
one
day
challeng
respiratori
diseas
less
sever
anim
treat
viral
load
lung
reduc
howev
therapeut
treatment
day
one
challeng
less
efficaci
prevent
develop
sever
respiratori
diseas
treat
anim
develop
bronchointerstiti
pneumonia
similar
sever
control
anim
thu
mab
administr
may
effect
prophylact
treatment
regimen
rather
treatment
mer
sinc
initi
identif
middl
east
respiratori
syndrom
coronaviru
merscov
caus
agent
sever
respiratori
diseas
case
detect
fatal
high
casefat
rate
merscov
infect
underlin
urgent
need
effect
treatment
reduc
burden
diseas
convalesc
plasma
therapi
suggest
promis
option
improv
diseas
outcom
mer
patient
consortium
metaanalysi
studi
efficaci
convalesc
plasma
therapi
sar
patient
show
reduc
casefat
rate
reduc
time
discharg
patient
treatment
administ
earli
diseas
cours
howev
qualiti
studi
includ
metaanalysi
consid
low
moder
high
risk
bia
mairjenkin
et
al
proof
concept
therapeut
prophylact
approach
convalesc
plasma
mer
cov
merscovneutr
serum
egyptian
dromedari
camel
natur
infect
merscov
transfer
ifnar
mice
transduc
adenoviru
express
human
inocul
merscov
result
reduc
weight
loss
lung
patholog
treat
anim
compar
control
polyclon
immunoglobulin
prepar
plasma
transchromosom
cow
hors
vaccin
merscov
also
effect
reduc
lung
viru
titer
administ
mice
one
day
inocul
merscov
zhao
et
al
howev
despit
promis
result
mous
model
high
casefat
rate
human
low
neutral
antibodi
titer
survivor
inabl
mani
survivor
function
plasma
donor
due
underli
health
issu
consider
hurdl
implement
convalesc
plasma
therapi
mer
patient
arabi
et
al
monoclon
antibodi
mab
treatment
could
provid
altern
convalesc
plasma
sever
neutral
monoclon
antibodi
develop
test
anim
model
agraw
et
al
http
receiv
april
receiv
revis
form
june
accept
june
corti
et
al
houser
et
al
johnson
et
al
li
et
al
pascal
et
al
qiu
et
al
two
fulli
human
neutral
monoclon
antibodi
bind
previous
describ
distinct
epitop
receptorbind
domain
merscov
spike
protein
pascal
et
al
treatment
mice
express
human
control
mous
element
either
inocul
merscov
significantli
reduc
viru
titer
lung
similarli
treatment
mice
inocul
merscov
also
reduc
viru
titer
lung
inocul
common
marmoset
merscov
result
coalesc
bronchointerstiti
pneumonia
clear
sign
respiratori
diseas
may
requir
euthanasia
chan
et
al
falzarano
et
al
evalu
abil
human
neutral
mab
reduc
diseas
sever
viru
replic
lung
common
marmoset
inocul
merscov
upon
prophylact
therapeut
treatment
model
clear
clinic
benefit
upon
prophylact
treatment
mab
howev
effect
therapeut
mab
treatment
diseas
cours
limit
anim
experi
approv
institut
anim
care
use
committe
rocki
mountain
laboratori
nih
carri
certifi
staff
associ
assess
accredit
laboratori
anim
care
aaalac
intern
accredit
facil
accord
institut
guidelin
anim
use
follow
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
avail
http
grantsnihgovgrantsolaw
referencesphspolicylabanimalspdf
guid
care
use
laboratori
anim
avail
http
grantsnihgov
grantsolawguideforthecareanduseoflaboratoryanimalspdf
institut
biosafeti
committe
ibc
approv
work
infecti
merscov
strain
condit
sampl
inactiv
perform
accord
ibcapprov
standard
oper
procedur
remov
specimen
high
contain
evalu
effect
neutral
monoclon
antibodi
treatment
merscov
diseas
outcom
use
common
marmoset
callithrix
jacchu
merscov
infect
model
recapitul
sever
respiratori
diseas
observ
hospit
patient
anim
randomli
assign
group
inocul
describ
previous
falzarano
et
al
briefli
inocul
merscov
strain
perform
intranas
per
nare
oral
intratrach
ocular
per
eye
dmem
contain
total
dose
anim
treat
mab
isotyp
control
antibodi
thu
nonspecif
treatment
control
experi
vitro
neutral
mab
merscov
bind
discret
epitop
merscov
spike
protein
receptor
bind
domain
pascal
et
al
treatment
group
consist
three
femal
three
male
common
marmoset
receiv
singl
treatment
intraven
volum
ml
depend
bodyweight
indic
tabl
anim
observ
twice
daili
clinic
sign
diseas
use
standard
score
sheet
describ
previous
falzarano
et
al
base
score
sheet
euthanasia
indic
clinic
score
predetermin
endpoint
experi
day
post
inocul
dpi
clinic
exam
perform
dpi
anaesthet
anim
exam
day
clinic
paramet
bodyweight
respir
rate
collect
well
dorsalventr
later
radiograph
blood
sampl
termin
blood
sampl
obtain
sampl
follow
tissu
collect
conjunctiva
nasal
mucosa
tonsil
trachea
four
lung
lobe
mediastin
lymph
node
liver
spleen
kidney
bladder
vero
passag
kindli
provid
depart
virosci
erasmu
medic
center
rotterdam
netherland
propag
cell
dmem
sigma
supplement
fetal
calf
serum
logan
mm
lglutamin
lonza
uml
penicillin
streptomycin
gibco
viru
isol
medium
cell
maintain
dmem
supplement
fetal
calf
serum
mm
lglutamin
uml
penicillin
streptomycin
twofold
serial
dilut
heatinactiv
min
marmoset
sera
prepar
dmem
contain
fetal
calf
serum
mm
lglutamin
uml
penicillin
streptomycin
viru
ad
incub
mix
ad
cell
dpi
well
score
cytopath
effect
viru
neutral
titer
express
reciproc
valu
highest
dilut
serum
still
inhibit
viru
replic
tissu
mg
homogen
rlt
buffer
rna
extract
use
rneasi
kit
qiagen
accord
manufactur
instruct
detect
viral
rna
rna
use
onestep
realtim
rtpcr
upe
assay
corman
et
al
use
rotorgen
probe
kit
qiagen
accord
instruct
manufactur
run
standard
dilut
titer
viru
stock
run
parallel
calcul
equival
sampl
histopatholog
immunohistochemistri
perform
marmoset
tissu
fixat
day
neutralbuff
formalin
embed
paraffin
tissu
section
stain
hematoxylin
eosin
detect
antigen
immunohistochemistri
perform
use
inhous
rabbit
polyclon
antiserum
primari
antibodi
quantit
antigenposit
lung
tissu
done
describ
previous
basel
et
al
briefli
section
lung
anim
necropsi
dpi
label
merscov
antigen
digit
use
aperio
digit
slide
scanner
leica
analyz
use
posit
pixel
count
algorithm
imagescop
version
leica
statist
analys
perform
use
graphpad
prism
softwar
version
test
whether
treatment
neutral
mab
reduc
diseas
sever
caus
merscov
common
marmoset
group
six
marmoset
treat
intraven
infus
mab
indic
tabl
control
anim
treat
mgkg
nonmerscovsbind
isotyp
control
therapeut
efficaci
two
differ
dose
test
first
experi
experi
includ
one
group
three
controltr
anim
two
group
treat
mgkg
respect
treat
h
inocul
merscov
result
first
experi
show
limit
efficaci
antibodi
treatment
second
experi
perform
experi
includ
one
group
three
controltr
anim
two
group
treat
mgkg
combin
concentr
mg
kg
anim
treat
h
inocul
merscov
anim
randomli
assign
follow
group
marmoset
tabl
three
anim
control
group
group
treat
prophylact
day
three
anim
treat
therapeut
day
mgkg
marmoset
group
ii
treat
prophylact
day
mgkg
group
iii
treat
prophylact
day
combin
mgkg
group
iv
treat
therapeut
day
mgkg
group
v
treat
therapeut
day
mgkg
day
post
inocul
dpi
serum
collect
anim
determin
level
merscovneutr
antibodi
expect
neutral
antibodi
merscov
detect
anim
group
infus
control
mab
fig
anim
group
ii
iii
treat
prophylact
high
neutral
antibodi
titer
time
inocul
merscov
day
rang
individu
anim
five
six
anim
group
ii
neutral
titer
drop
dpi
fig
group
iv
neutral
titer
dpi
rang
drop
dpi
one
anim
group
euthan
due
sever
diseas
dpi
neutral
titer
anim
dpi
remain
high
time
euthanasia
sever
diseas
observ
anim
unlik
due
low
neutral
antibodi
titer
anim
group
v
receiv
higher
mab
dose
group
iv
reflect
level
neutral
antibodi
detect
serum
rang
dpi
titer
drop
dpi
anim
titer
rang
fig
day
anim
challeng
merscov
isol
describ
previous
falzarano
et
al
inocul
anim
close
monitor
sign
diseas
clinic
score
assign
accord
previous
assign
score
sheet
falzarano
et
al
anim
group
treat
control
mab
show
sign
diseas
fig
decreas
activ
start
dpi
anim
also
increas
respir
start
dpi
last
end
experi
dpi
contrast
four
six
marmoset
group
ii
iii
treat
prophylact
differ
mab
show
obviou
diseas
sign
fig
loss
appetit
anim
may
result
repeat
anesthesia
remain
two
anim
group
ii
iii
show
decreas
activ
one
anim
group
show
increas
respir
marmoset
group
iv
v
treat
therapeut
differ
dose
show
decreas
activ
start
dpi
last
throughout
experi
one
anim
show
increas
respir
sever
day
inocul
fig
one
anim
group
iv
develop
dyspnea
cyanosi
hypothermia
bodi
temperatur
dpi
euthan
anim
group
lost
bodyweight
inocul
merscov
anim
lose
start
weight
experi
fig
weight
loss
group
ii
iii
reduc
maximum
observ
weight
loss
respect
weight
loss
compar
control
group
observ
anim
group
iv
group
v
five
six
anim
show
weight
loss
rang
fig
respir
rate
establish
anim
clinic
exam
indic
respiratori
diseas
respir
rate
clearli
increas
anim
control
group
fig
clear
increas
observ
anim
group
ii
anim
group
iii
group
iv
v
clear
increas
respir
rate
anim
fig
dorsalventr
later
xray
collect
monitor
sign
pneumonia
dpi
analyz
clinic
veterinarian
accord
standard
score
system
cumul
xray
score
anim
dpi
except
one
anim
euthan
dpi
xray
score
dpi
display
shown
fig
anim
treat
control
mab
group
develop
lung
infiltr
visibl
xray
two
lung
lobe
pulmonari
infiltr
less
promin
anim
group
ii
anim
group
iii
pulmonari
infiltr
group
iv
v
rang
absent
sever
fig
anim
euthan
dpi
determin
viral
load
tissu
perform
histopatholog
sinc
lung
main
site
merscov
replic
common
marmoset
compar
viral
load
determin
qrtpcr
corman
et
al
four
lung
lobe
group
viral
load
lung
lobe
consist
high
variat
anim
much
larger
group
treat
merscovneutr
antibodi
fig
analysi
complet
lung
viral
load
fig
show
viral
load
anim
treatment
group
iii
iv
statist
significantli
lower
oneway
anova
dunnett
multipl
comparison
test
anim
group
viral
load
lung
anim
treatment
group
ii
v
differ
significantli
group
note
anim
group
iv
euthan
dpi
exclud
analysi
howev
even
anim
includ
still
statist
signific
differ
lung
viral
load
group
vs
group
iv
differ
smaller
differ
correl
dose
mab
administ
anim
variou
tissu
also
test
presenc
viral
rna
viral
load
respiratori
tissu
lymph
node
drain
tissu
often
significantli
higher
anim
group
treat
group
iiv
extrarespiratori
tissu
signific
differ
viral
load
anim
control
group
versu
treatment
group
fig
note
anim
group
iv
euthan
dpi
due
sever
diseas
exclud
analys
viral
load
tissu
anim
display
separ
fig
anim
euthan
dpi
develop
multifoc
coalesc
minim
mark
subacut
bronchointerstiti
pneumonia
type
ii
pneumocyt
hyperplasia
describ
previous
basel
et
al
falzarano
et
al
histopatholog
differ
sever
natur
pneumonia
control
anim
group
prophylact
treat
anim
group
ii
group
iii
anim
develop
slightli
less
sever
lesion
compar
control
fig
differ
sever
natur
pneumonia
anim
control
group
anim
treat
therapeut
neutral
mab
group
iv
v
fig
tabl
dpi
serum
collect
test
presenc
neutral
antibodi
treatment
group
group
mgkg
administ
prophylact
therapeut
three
anim
group
ii
mgkg
prophylact
group
iii
mgkg
mgkg
prophylact
group
iv
mgkg
regn
therapeut
group
v
mgkg
therapeut
tabl
inocul
anim
observ
twice
daili
clinic
sign
diseas
score
use
clinic
score
system
prepar
common
marmoset
falzarano
et
al
dpi
clinic
exam
perform
bodyweight
b
respir
rate
c
determin
radiograph
taken
radiograph
use
score
individu
lung
lobe
sever
pulmonari
infiltr
clinic
veterinarian
accord
standard
score
system
normal
mild
interstiti
pulmonari
infiltr
moder
pulmonari
infiltr
perhap
partial
cardiac
border
effac
small
area
pulmonari
consolid
seriou
interstiti
infiltr
alveolar
pattern
air
bronchogram
cumul
xray
score
sum
score
four
individu
lung
lobe
per
anim
symbol
indic
statist
signific
differ
anova
dunnett
multipl
comparison
group
ii
group
iii
group
group
iv
group
v
treatment
group
group
mgkg
group
ii
mgkg
prophylact
group
iii
mgkg
mgkg
prophylact
group
iv
mgkg
therapeut
group
v
mgkg
therapeut
symbol
present
differ
statist
signific
immunohistochemistri
perform
lung
tissu
anim
use
antibodi
look
distribut
viral
antigen
small
number
pneumocyt
rare
macrophag
posit
viral
antigen
anim
posit
cell
predominantli
associ
area
pneumonia
visual
differ
distribut
viral
antigen
five
experiment
group
fig
addit
quantit
analysi
number
antigenposit
pixel
indic
differ
number
merscov
infect
cell
anim
control
group
anim
treat
prophylact
therapeut
except
significantli
higher
number
antigenposit
cell
left
lung
anim
group
iv
compar
group
fig
despit
urgent
need
effect
treatment
mer
larg
number
monoclon
polyclon
antibodi
prepar
develop
progress
beyond
test
small
anim
model
three
mab
evalu
nonhuman
primat
model
merscov
infect
prophylact
efficaci
mab
determin
rhesu
macaqu
treatment
result
reduct
patholog
lung
volum
comput
tomographi
common
marmoset
model
merscov
infect
therapeut
efficaci
mab
seen
anim
treat
h
day
post
inocul
h
post
inocul
van
doremalen
et
al
although
improv
clinic
diseas
seen
compar
mocktreat
control
anim
neither
treatment
prevent
merscov
diseas
test
prophylact
therapeut
efficaci
neutral
mab
merscov
common
marmoset
model
moder
sever
mer
clinic
benefit
mab
prophylaxi
studi
reduct
clinic
diseas
score
prophylact
treat
anim
effect
antibodi
administr
lung
viral
load
lung
histopatholog
consist
although
clinic
score
reduc
prophylact
treatment
group
viral
lung
load
histolog
tabl
dpi
anim
euthan
tissu
sampl
collect
lung
lobe
rna
extract
viral
load
determin
equival
per
gram
tissu
individu
anim
lung
lobe
indic
averag
standard
deviat
per
group
b
oneway
anova
dunnett
multipl
comparison
test
perform
determin
statist
signific
differ
group
group
indic
p
treatment
group
group
mgkg
group
ii
mg
kg
prophylact
group
iii
mgkg
mgkg
prophylact
group
iv
mgkg
therapeut
group
v
mgkg
therapeut
tabl
dpi
anim
euthan
tissu
sampl
collect
respiratori
extrarespiratori
b
tissu
rna
extract
viral
load
determin
equival
per
gram
tissu
twoway
anova
tukey
multipl
comparison
test
perform
determin
statist
signific
differ
group
group
p
p
p
p
treatment
group
group
mgkg
group
ii
mgkg
prophylact
group
iii
mgkg
mg
kg
prophylact
group
iv
mgkg
therapeut
group
v
mgkg
therapeut
caption
next
page
e
de
wit
et
al
antivir
research
lesion
significantli
reduc
anim
group
iii
treat
combin
anim
treat
therapeut
observ
smaller
clinic
benefit
clinic
diseas
score
return
normal
sooner
treat
anim
nevertheless
one
therapeut
treat
anim
euthan
due
sign
sever
respiratori
diseas
howev
differ
sever
lung
patholog
control
therapeut
treat
anim
thu
differ
sever
bronchointerstiti
pneumonia
marmoset
model
poor
correl
lung
viral
load
clinic
diseas
lung
patholog
observ
mabtreat
anim
may
explain
fact
immun
respons
import
contributor
pathogen
merscov
nonhuman
primat
basel
et
al
studi
immunosuppress
rhesu
macaqu
viral
load
lung
almost
higher
control
lung
patholog
reduc
prescott
et
al
lung
viral
load
statist
significantli
lower
anim
treat
prophylact
combin
two
neutral
antibodi
compar
control
anim
case
anim
treat
prophylact
singl
neutral
antibodi
total
dose
moreov
lung
lesion
anim
treat
combin
antibodi
slightli
less
sever
control
thu
combin
two
neutral
antibodi
target
differ
epitop
spike
protein
may
result
better
treatment
efficaci
could
consid
test
prophylaxi
futur
studi
previous
publish
common
marmoset
studi
show
clinic
improv
therapeut
mab
treatment
inocul
merscov
mab
treatment
start
sooner
inocul
h
present
studi
van
doremalen
et
al
one
studi
treatment
repeat
day
post
inocul
van
doremalen
et
al
one
factor
potenti
affect
treatment
efficaci
studi
time
peak
viru
replic
lung
inocul
common
marmoset
may
possibl
inhibit
viru
replic
neutral
antibodi
long
level
infecti
viru
particl
lung
still
rel
low
anoth
potenti
issu
could
intraven
administr
rout
antibodi
upon
intraven
administr
concentr
antibodi
lung
sever
hundr
fold
lower
serum
dallacqua
et
al
hart
et
al
penetr
site
viru
replic
may
hamper
even
tissu
damag
occur
alveolar
septa
thicken
one
indic
penetr
mab
lung
might
least
partial
explain
limit
reduct
lung
viral
load
observ
fact
viral
load
almost
tissu
lower
four
treatment
group
control
anim
would
thu
interest
investig
altern
rout
administr
nebul
maxim
concentr
mab
lung
respaud
et
al
although
merscov
diseas
cours
common
marmoset
shorter
human
patient
therebi
potenti
shorten
window
opportun
success
treatment
model
start
treatment
dpi
coincid
onset
clinic
sign
impact
patient
treatment
limit
time
health
seek
behavior
patient
merscov
neutral
mab
may
still
use
patient
manag
merscov
outbreak
mani
merscov
outbreak
center
around
health
care
set
presenc
comorbid
mer
patient
link
poor
prognosi
thu
one
could
consid
prophylact
treatment
specif
target
popul
famili
member
sever
mer
case
identifi
health
care
facil
similar
current
practic
mab
prophylaxi
children
increas
risk
seriou
lower
respiratori
tract
infect
caus
respiratori
syncyti
viru
american
academi
pediatr
committe
infecti
american
academi
pediatr
bronchiol
guidelin
moreov
possibl
neutral
mab
provid
therapeut
benefit
combin
antivir
treatment
regimen
current
investig
mer
edw
ff
ao
evh
elh
gs
ds
kje
hf
conflict
interest
declar
ns
cak
employe
regeneron
pharmaceut
inc
histopatholog
chang
lung
common
marmoset
inocul
merscov
treat
neutral
mab
five
group
six
marmoset
inocul
merscov
treat
mab
indic
tabl
dpi
anim
euthan
lung
sampl
collect
stain
hematoxylin
eosin
b
e
g
h
j
k
n
polyclon
antibodi
c
f
l
one
repres
imag
chosen
group
b
c
group
ii
e
f
group
iii
g
h
group
iv
j
k
l
group
v
n
treatment
group
group
mgkg
group
ii
mgkg
prophylact
group
iii
mgkg
mgkg
prophylact
group
iv
mgkg
therapeut
group
v
mgkg
therapeut
panel
chosen
reflect
overal
histopatholog
lung
accur
therefor
collect
lung
lobe
howev
ihc
panel
consecut
tissu
section
magnif
indic
top
figur
tabl
dpi
anim
euthan
lung
sampl
collect
stain
polyclon
antibodi
slide
four
lung
lobe
anim
digit
antigenposit
pixel
quantifi
use
imagescop
posit
pixel
algorithm
percentag
antigenposit
pixel
calcul
number
pixel
stain
merscov
antigen
divid
total
number
stain
pixel
ie
nonstain
area
air
space
exclud
analysi
twoway
anova
dunnett
multipl
comparison
test
perform
determin
statist
signific
differ
group
group
indic
p
treatment
group
group
mgkg
group
ii
mgkg
prophylact
group
iii
mgkg
mgkg
prophylact
group
iv
mgkg
therapeut
group
v
mgkg
therapeut
